Arvinas Presents Preclinical Data on ARV-393 in Lymphoma
Arvinas presented preclinical data on its BCL6 degrader ARV-393 in lymphoma.
Related stories
Apple CEO Says Timing of iPhone Supply-Demand Balance Is Uncertain
Apple’s CEO said the company cannot predict when iPhone supply and demand will balance.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
Argentina’s Metalfor Seeks Preventive Insolvency Proceedings
The agricultural machinery manufacturer sought preventive insolvency proceedings after months of financial crisis and layoffs.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
LUX Infusion Acquires Be Well Memory’s Specialty Infusion Business
LUX Infusion says the acquisition expands access to clinician-led specialty infusion care in Nebraska.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
Embraer Shares Rise More Than 4% After Greece KC-390 Order
Embraer shares rose more than 4% after Greece placed an order for KC-390 aircraft.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
Minda Corporation Q2 Revenue Rises 42.6% to Rs 2,189 Crore
Consolidated operating revenue increased year on year from Rs 1,535 crore in the corresponding period last year. EV products accounted for 35% of new orders.
M impact | EQUITY | Nov 03, 2026, 03:33 PM UTC
Intuitive Machines Secures Third NASA Contract in Six Months
The company will provide its spacecraft platform and system integration for NASA’s Falcon-Radar satellite. LUNR shares were up about 7% at the time of writing.
M impact | EQUITY | Nov 03, 2026, 03:32 PM UTC